RA Capital declares 14.6% of Bambusa Therapeutics after its IPO
RA Capital Management holds 14.6% of newly listed Bambusa Therapeutics and says it is investing, with no plan to change control.
The filing
13D
14.6%
Of the shares
$111.37M
Value
Active
Investor
B
Bambusa Therapeutics, Inc. Common stock
Holds 7,429,758 shares
Stated purpose
RA Capital says it holds Bambusa shares for investment, not to change control, may buy or sell more, and talks with the board through its partner who is a director.
Declared to the SEC, the US stock market watchdog (Schedule 13D), after the 5% threshold was crossed on October 30, filed on November 6.
AI analysis
Nov 6
With TrueWallet Pro
What this filing changes for the stock, what the fund wants, and what it does not say. Upgrade to Pro from the TrueWallet app.